A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

BLR Bio LLC has announced new data on BLR-200, its lead compound for systemic sclerosis and lung fibrosis. In the new study, BLR-200 demonstrated the ability to reduce key disease tissue markers for ...

An already approved cancer drug, Yervoy (ipilimumab), improved lung repair ability in a study of mice with idiopathic ...